reports
- Livio Luyten
Holdings Report May 2025 KBCS Holdings Universe Returns 2.2% During Ma...
1M Performance - Absolute: During May'25 (1M period), the KBCS Holdings Universe posted a return of +2.2% which was mainly driven by multi-asset holdings (+2.6%) while single-asset holdings posted a smaller return of +1.2%. The 3 top performers during the period were Gimv (+12.1%), KBC Ancora (+11.1%) and Ackermans & van Haaren (+4.1%) while the 3 worst performers were Solvac (-2.8%), Groupe Bruxelles Lambert (-0.8%) and Heineken Holding (-0.3%). YTD Performance - Relative: On a YTD basis (as o...
GBLB GROUPE BRUXELLES LAMBERT SA
HAL HAL TRUST
DIE D'IETEREN SA
SOF SOFINA SA
SOLV SOLVAC S.A.
GIMB GIMV NV
QFG QUEST FOR GROWTH
ACKB ACKERMANS & VAN HAAREN NV
TUB FINANCIERE DE TUBIZE S.A.
HEIO HEINEKEN HOLDING N.V.
KBCA KBC ANCORA SCA
TEXF TEXAF
BREB BREDERODE S.A.
TINC TINC COMM. VA
EXO EXOR N.V.
ROCK WHITESTONE GROUP
- Wim Lewi
TINC Rights Issue, share price starts trading ex-right today
Yesterday morning 8h00, TINC announced a rights issue. This morning the shares start trading ex-right. Based on the closing price of €10.92, the TERP amounts to €10.525 per share, this indicates a theoretical right value of €0.395. The discount of the subscription price to NAV (ex-dividend) amounts to 25.4%. The company also reported 1Q25 results, which we discuss briefly below. We note that TINC increased its net debt position to 101.3m. We maintain our rating at Suspended as KBC Securities act...
- Hilde Van Boxstael
- Lynn Hautekeete
- Wim Lewi
- Guy Sips
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Thomas Vranken
- Wim Lewi
- Livio Luyten
TINC TINC announces rights issue for up to €113.2m
This morning, TINC launched a rights issue of up to €113.2m at a subscription price of €9.34 with a ratio of 1 for 3. This represents a 10.11% discount to the TERP of €10.39. The proceeds will be mainly used to fund its €143.2m in committed investments and work towards the ambition to double the portfolio by 2030. Infravest has committed up to €50m in the offering. They currently hold 21.32% of TINC. The rights subscription and trading period runs from 5 to 17 June 2025, with settlement and tra...
World's Leading Institutions and IBA launch Proton Therapy Academy to ...
World's Leading Institutions and IBA launch Proton Therapy Academy to shape the future of cancer care New global education initiative unveiled at 2025 PTCOG Annual Conference Louvain-la-Neuve, Belgium, 4 June 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces the launch of Proton Therapy Academy, a new global training and education initiative developed in partnership with prominent institutions in the field of proton therapy. The Academy has be...
Des institutions mondiales de renom et IBA lancent la Proton Therapy A...
Des institutions mondiales de renom et IBA lancent la Proton Therapy Academy pour élaborer l'avenir des soins contre le cancer Nouvelle initiative mondiale de formation présentée lors de la conférence annuelle PTCOG 2025 Louvain-la-Neuve, Belgique, le 4 juin 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, annonce aujourd'hui le lancement de la Proton Therapy Academy, une nouvelle initiative de formation et d’éducation développée en parte...
Iba – Acquisition of Own Shares - Completion of the Share Buyback Prog...
Iba – Acquisition of Own Shares - Completion of the Share Buyback Program Immediate Release – May 30th, 2025 Louvain-la-Neuve, Belgium, May 30th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until Decembe...
IBA – ACQUISITION D’ACTIONS PROPRES - FIN DU PROGRAMME DE RACHAT D’ACT...
IBA – ACQUISITION D’ACTIONS PROPRES - FIN DU PROGRAMME DE RACHAT D’ACTIONS Publication immédiate – 30 mai 2025 Louvain-la-Neuve, Belgique, 30 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 24 mars 2025. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 650.000 actions ordinaires IBA selon les termes d'...
Iba – Acquisition of Own Shares
Iba – Acquisition of Own Shares Immediate Release – May 26th, 2025 Louvain-la-Neuve, Belgium, May 26th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from March 25th...
IBA – ACQUISITION D’ACTIONS PROPRES
IBA – ACQUISITION D’ACTIONS PROPRES Publication immédiate – 26 mai 2025 Louvain-la-Neuve, Belgique, 26 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 24 mars 2025. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 650.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 31 décembre ...
- ING Helpdesk
Benelux Morning Notes
Ackermans & van Haaren: Solid 1Q25. Ascencio: Resilient results. Gimv: NAV a tad higher than expected, underlying companies surprisingly strong. IBA: Soft start in Technologies, 2025 and 2028 guidance reiterated. OCI: In-line 1Q25 trading update. Vopak: IPO of AVTL - value coming to the surface
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Wim Hoste
- Wim Lewi
IBA Business Update Q1 2025
IBA Business Update Q1 2025 Year starting on track Louvain-la-Neuve, Belgium, 22 May 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the first quarter of 2025. Group Overview Solid commercial momentum, particularly in IBA Clinical Equipment and Services backlog at €1.5 billion, with conversion executed in line with plan€ 9 million1 positive net cash position, decreasing vs. year-end. Foreseen backlog delivery activities impacting inventory and contract in progress build-up. New ventures (IBA Investme...
IBA déclaration intermédiaire - premier trimestre 2025
IBA déclaration intermédiaire - premier trimestre 2025 Début d’année conforme aux attentes Louvain-la-Neuve, Belgique, le 22 mai 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules, publie aujourd'hui la revue de ses activités pour le premier trimestre se terminant le 31 mars 2025. Vue d'ensemble des activités du Groupe Solide dynamique commerciale, en particulier pour l’entité IBA ClinicalCarnet de commandes d'équipements et de services à 1,5 milliard d'euros, dont la conversion évolue comme prévuPosition de trésorerie net...
- Guy Sips
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Thomas Vranken
IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiw...
IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiwan The Cyclone® IKON is IBA’s high energy and high-capacity cyclotron which offers the largest energy spectrum for the production of PET and SPECT isotopes from 13 MeV to 30 MeV Louvain-La-Neuve, Belgium, May 21, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, announces it has signed a contract with PET Pharm Bio to install a PET and SPECT isotopes production center in Taipei, Taiwan. PET Ph...
IBA et PET Pharm Bio signe un contrat pour l’installation d’un Cyclone...
IBA et PET Pharm Bio signe un contrat pour l’installation d’un Cyclone® IKON à Taiwan Le Cyclone® IKON est le cyclotron haute énergie et haute capacité d'IBA qui offre le plus grand spectre d'énergie pour la production d’isotopes TEP et TEMP de 13 MeV à 30 MeV. Louvain-la-Neuve, Belgique, le 21 mai 2025 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et le principal fournisseur de solutions de production de radiopharmaceutiques, annonce avoir signé un contrat avec PET Pharm Bio pour installer un centre de production d'isotopes...
IBA – ACQUISITION OF OWN SHARES
IBA – ACQUISITION OF OWN SHARES Immediate Release – May 19th, 2025 Louvain-la-Neuve, Belgium, May 19th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from March ...
IBA – ACQUISITION D’ACTIONS PROPRES
IBA – ACQUISITION D’ACTIONS PROPRES Publication immédiate – 19 mai 2025 Louvain-la-Neuve, Belgique, 19 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 24 mars 2025. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 650.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 31 décembr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.